RT Conference Proceedings
T1 A Phase I/II Trial of IO102 and Pembrolizumab With/Without Chemotherapy as First-line Treatment of Metastatic NSCLC
A1 Provencio, M.
A1 Spicer, J.
A1 Garrido, P.
A1 Trigo Perez, J. M.
A1 Viteri, S.
A1 Bosch-Barrera, J.
A1 Insa, A.
A1 Felip, E.
A1 De Castro Carpeno, J.
A1 Coart, E.
A1 Schmidt, E.
A1 Christiansen, A.
A1 Andersen, M. Hald
A1 Zocca, M.
A1 Ehrnrooth, E.
A1 Paz-Aras, L.
K1 NSCLC
K1 Vaccine
K1 Pembrolizumab
PB Elsevier science inc
SN 1556-0864
YR 2019
FD 2019-10-01
LK https://hdl.handle.net/10668/26948
UL https://hdl.handle.net/10668/26948
LA en
DS RISalud
RD Apr 4, 2025